PRTA
$9.00
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...
Recent News
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Prothena Corporation plc Q4 2025 Earnings Call Summary
Moby summary of Prothena Corporation plc's Q4 2025 earnings call
Prothena Corp PLC (PRTA) Q4 2025 Earnings Call Highlights: Strategic Advancements and Financial ...
Prothena Corp PLC (PRTA) reports strong cash position and strategic progress in clinical trials, despite substantial net loss in 2025.
Prothena Q4 Earnings Call Highlights
Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash burn outlook for 2026. Management repeatedly emphasized that Prothena’s pipeline is primarily advanced